Hong-Jae Chon

37PUBLICATIONS

168CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersMolecular targetsHaematological tumours

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (37)

Sort by Publication Date:

|Jun 09, 2026

A phase Ib/2a study of fostrox in combination with lenvatinib as second line therapy in patients with advanced hepatocellular carcinoma.

|Feb 12, 2026

Response: Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC.

Jung Sun Kim, Thomas Yau, Hong Jae Chon

|Feb 02, 2026

Prognostic Value of FDG PET/CT Parameters in Patients With Advanced Biliary Tract Cancer Receiving Gemcitabine, Cisplatin, and Nab-Paclitaxel.

Jeong Won Lee, Sang Mi Lee, Beodeul Kang

|Dec 26, 2025

Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study.

Jung Sun Kim, Jeffrey Wong, San-Chi Chen

|Dec 18, 2025

Elevated antidrug antibodies against atezolizumab and associated clinical outcomes in advanced non-small-cell lung cancer.

Miran Jang, Chan Kim, So Jung Kong

|Nov 12, 2025

Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers.

Margherita Rimini, Lorenzo Fornaro, Masafumi Ikeda

Pageof 7

Frequent Collaborators

14 joint publications

Chan Kim

Jung Sun Kim

Jaekyung Cheon

Hannah Yang

Yun-Beom Sang

Yoo Changhoon

Beodeul Kang

Masatoshi Kudo

Won Suk Lee

Lorenza Rimassa

Frequent Collaborators

14 joint publications

Chan Kim

5 joint publications

Jung Sun Kim

4 joint publications

Jaekyung Cheon

4 joint publications

Hannah Yang